All entries for: Eli Lilly & Company

June 2, 2024

Eli Lilly & Company

Negative Outlook

Indianapolis, IN
10,001-50,000 employees
10001-50000 employees

“Specifically, Ricks referred to the IRA’s nine-year restriction on market exclusivity before government price-setting for small-molecule drugs as “terminating ideas before they have time to even grow roots.”

“I think that we’re going to miss the next Keytruda. And that’s why we’re raising the points that we are,” Ricks stressed.”

Disease Area: Oncology
Drug Type: Small Molecule
November 2, 2023

Eli Lilly & Company

Negative Outlook

Indianapolis, IN
10,001-50,000 employees
10001-50000 employees

“Global concern over access to and affordability of pharmaceutical products continues to drive regulatory and legislative debate and action, as well as worldwide cost containment efforts by governmental authorities. Such measures include the use of mandated discounts, price reporting requirements, mandated reference prices, restrictive formularies, changes to available intellectual property protections, as well as other efforts. In August 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (IRA).”

Disease Area: Multiple, Oncology
Drug Type: Biologic
August 8, 2023

Eli Lilly & Company

Negative Outlook

Indianapolis, IN
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic
April 27, 2023

Eli Lilly & Company

Negative Outlook

Indianapolis, IN
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic
November 1, 2022

Eli Lilly & Company

Negative Outlook

Indianapolis, IN
10,001-50,000 employees
10001-50000 employees

• Potential Significant Impact if Drugs Selected: “It is too soon to tell how the U.S. government will set these prices as the law specifies a ceiling price, but not a minimum or floor price. One or more significant Lilly products may be selected, which would have the effect of accelerating revenue erosion prior to patent expiry. The effect of reducing prices and reimbursement for certain of our products could significantly impact our business and consolidated results of operations” • Small Molecule Investment Strategy: “The IRA may meaningfully influence our and pharmaceutical industry business strategies. In particular it may reduce the attractiveness of investment in small molecule innovation” • Potential Legal Uncertainty: “Provisions of the IRA may be subject to legal challenges or other reformation, and the full effect of the IRA on our business and the pharmaceutical industry remains uncertain. Additional policies, regulations, legislation, or enforcement, including those proposed and/or pursued by the U.S. Congress and executive branch of the U.S. administration and other regulatory authorities worldwide, could adversely impact our business and consolidated results of operations”

Disease Area: Multiple, Oncology
Drug Type: Biologic
November 1, 2022

Eli Lilly & Company

Negative Outlook

Indianapolis, IN
10,001-50,000 employees
10001-50000 employees

“The law “may reduce the attractiveness of investment in small molecule innovation,” Lilly wrote in its quarterly earnings filing, referring to drugs that are made as pills or tablets.”

Disease Area: Oncology
Drug Type: Small Molecule
November 1, 2022

Eli Lilly & Company

Discontinued Drug, Discontinued Research

Indianapolis, IN
10,001-50,000 employees
10001-50000 employees

Eli Lilly laid blame Tuesday afternoon on President Joe Biden’s Inflation Reduction Act as the reason it scrapped a $40 million cancer drug.

As part of its third quarter update earlier Tuesday morning, the Big Pharma revealed it had removed a Phase I drug licensed from Fosun Pharma, a BCL2 inhibitor that had been undergoing studies for a variety of blood cancers. Though the reasoning had been initially unclear, an Eli Lilly spokesperson told Endpoints News in an email that “in light of the Inflation Reduction Act, this program no longer met our threshold for continued investment.”

Asked to explain how the IRA impacted this specific drug, the spokesperson highlighted the law’s impact on small molecule R&D.

“The IRA changes many dynamics for small molecules in oncology and when we integrated those changes with this program and its competitive landscape, the program’s future investment no longer met our threshold,” the spokesperson told Endpoints in a follow-up email.

1 Discontinued Drug: LOXO-338 (small molecule)
1 Discontinued Research Program

Disease Area: Oncology
Drug Type: Small Molecule
Scroll to Top